Momenta And Baxter To Team Up On Biosimilars As U.S. Regulatory Pathway Becomes Clearer
This article was originally published in The Pink Sheet Daily
Executive Summary
Momenta believes its biologic characterization approach combined with Baxter’s commercial expertise in biologics will put the companies’ joint effort in developing biosimilars over the top in what is poised to become a very competitive space.